Actelion to discuss US FDA approval of Uptravi (selexipag) for the treatment of pulmonary arterial hypertension Dienstag, 22. Dezember 2015 - 07:37

Dear member of the investment community

Actelion announced today that the United States Food and Drug Administration (FDA) has approved the use of the orally active, selective IP prostacyclin receptor agonist Uptravi (selexipag) for the treatment of pulmonary arterial hypertension (PAH).

An investor conference call & webcast will be held to discuss the approval at 14:00hrs on 05 January 2016.

Date/Time:

05 January 2016	14:00hrs - 15:00hrs	Basel (CET)
	13:00hrs - 14:00hrs	UK (GMT)
	8:00 a.m. - 9:00 a.m.	US (EST)

  
  
Conference Call and Webcast
Participants will find dial-in information and a link to the webcast on the Actelion website www.actelion.com at least 24hrs ahead of when the conference is due to start.

Webcast Replay:
The archived Investor Webcast will be available for replay through www.actelion.com approximately 60 minutes after the call has ended.